Develops and manufactures equipment for biopharmaceutical production. Provides consumables such as cell culture media and filters. Now — the numbers.
This is an established company with proven profits.
No real growth.
The gap is $2.5B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 710× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 50% below its peak. The market has trimmed its expectations for the company.
It pays out $0.08 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales fell about 0% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 710 times its annual profit. Even a small disappointment could hit the price hard.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.